Fig. 4: Tacrolimus elevates the mTOR activity and proliferation of renal cell carcinoma cell lines in vitro.
From: Tumorigenic role of tacrolimus through mTORC1/C2 activation in post-transplant renal cell carcinomas
Tacrolimus (TAC) enhances mTOR activity and promotes the proliferation of certain renal cell carcinoma cell lines, whereas mTOR inhibitors mostly attenuate these effects. a, b Western blot analyses of short- and long-term (72 h and 21-day) effect of TAC (10 ng/ml), rapamycin (RAPA, 10 ng/ml) and PP242 (1 μM) on mTOR activity markers. Samples were derived from the same experiment, and the blots were processed in parallel. c Effects of TAC, RAPA and PP242 on proliferation of HK-2 cells (72 h). Used concentrations were indicated in the figure. *p < 0.05, **P < 0.01 (one-way ANOVA with Tukey’s post hoc test, the significance compared to the control). d Long-term (21-day) effect of TAC (10 ng/ml) on A498 cell line. Proliferation was evaluated by cell counting. No cells were discarded during the experiment. p = 0.07 (paired t-test).
